The Efficacy of Octreotide LAR in Acromegalic Patients as Primary Therapy

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 88-129-Acromegaly & Prolactinoma
Clinical
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-94
Rafael Loch Batista*1, Viviane Castelo de Vasconcelos2, Ana Paula Cavalcante Normando2 and Marcos Sergio Neres da Silva2
1Hospital Santa Marcelina, Sao Paulo, Brazil, Sao Paulo SP, Brazil, 2Hospital Santa Marcelina, Sao Paulo, Brazil
Acromegaly is a chronic disease with signs and symptoms caused by excess circulating growth hormone (GH), which impairs the quality of life and reduces the life expectancy of affected patients. The treatment of acromegaly include surgery, radiation therapy and drugs. Tranesfenoidal surgery is the first choice of treatment, although there is evidence that drug treatment can be effective as primary therapy. Therefore, our study evaluated the effectiveness of drug therapy as primary therapy for acromegaly. Data collection was performed at the medical records of 12 patients from the outpatient clinic of the Hospital Santa Marcelina neuroendocrinology unit in the period from 2006 to 2012, who used drug treatment as primary therapy. There was a reduction in the levels of IGF-1, 6 and 12 months, 25 and 60%, with normalization of 25 and 30%, respectively. There was a significant reduction in IGF-1 levels at 6 months (p <0.001) and 12 months (p = 0.048), with no statistical difference in the decreases observed at 6 and 12 months (p = 0.275), showing that the therapeutic effectiveness is sustained at 12 months. Regarding the levels of GH, normalization obtained in only 18%, in contrast to the literature because we used the criteria of GH <1.0mcg / l. The therapeutic response was dependent on tumor size and is better in microadenomas in which decreased the tumor size by 40% of patients. We conclude that Octreotide LAR is effective in the treatment of acromegaly as primary treatment, supporting the fall in levels of IGF-1 during the study period (12 months).

Nothing to Disclose: RLB, VCDV, APCN, MSNDS

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm